Chapter 1 - Arbitrary Decrees: Science-Free Medicine

This is a listing of all citations in this chapter.

31

Elizabeth Fernandez, “Smoking Nearly Doubles the Rate of COVID-19 Progression,” UCSF (May 12, 2020).

32

Becky McCall, “Vitamin D Deficiency in COVID-19 Quadrupled Death Rate,” Medscape (Dec. 11, 2020).

33

Berkeley Lovelace, Jr., “CDC study finds about 78% of people hospitalized for Covid were overweight or obese,” CNBC (Mar. 8, 2021).

34

Carolyn Crist, “Study: In U.S., Lockdowns Added 2 Pounds per Month,” WebMD (Mar. 23, 2021).

35

M. Science, J. Johnstone, et al, “Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials,” CMA 184(10) (2012): 551-E561, doi:10.1503/cmaj.111990.

36

College of Physicians and Surgeons, “Statement on Public Health Information,” (Apr 30, 2021).

37

Emma Talkoff & Ashley Fetters Maloy, “The anti-vax wellness influencers,” Post Reports-Podcast (Oct. 1, 2021, 00:10:11). Also on Spotify, https://open.spotify.com/episode/2N9m96jw8o9QtrMHPoI5Aa (00:10:25)

38

Gabby Landsverk, “Long-term quarantines can weaken your immune system due to loneliness and stress. Here’s how to cope,” Insider (May 12, 2020).

39

American Psychological Association, “Stress Weakens the Immune System,” APA (Feb. 26, 2006).

40

Yale, “Harvey Risch, MD, PhD Biography,” Yale School of Public Health (Jul. 15, 2019).

41

Peter A. McCullough, et al., “The Pathophysiologic Basic and Clinical Rationale for Early Ambulatory Treatment of COVID-19,” V:134 I:1 The American Journal of Medicine P16-22, (Jan. 1, 2021), doi:https://doi.org/10.1016/j.amjmed.2020.07.003.

42

Peter A. McCullough et al., “Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).” Reviews in Cardiovascular Medicine 21 no. 4 (Dec. 2020): 517-530.

43

FLCCC, “Dr. Pierre Kory, M.P.A., M.D. curriculum vitae,” FLCCC Alliance.

44

Joel Rose, “U.S. Field Hospitals Stand Down, Most Without Treating Any COVID-19 Patients,” NPR, (May 7, 2020).

45

New York Times staff, “Nearly One-Third of U.S. Coronavirus Deaths Are Linked to Nursing Homes,” New York Times (Jun. 1, 2021).

46

New York Times staff, “Nearly One-Third of U.S. Coronavirus Deaths Are Linked to Nursing Homes,” New York Times (Jun. 1, 2021).

47

Front Line COVID-19 Critical Care Alliance, “The FLCCC Alliance,” FLCCC (2021).

48

Paul G. Harch, “Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure,” Medical Gas Research V10(2) (Apr.-Jun., 2020):61-62.

49

Scott A Gorenstein et al, “Hyperbaric oxygen therapy for COVID-19 patients with respiratory distress: treated cases versus propensity-matched controls,” Undersea & Hyperbaric Medical Society 47(3) (Third-quarter, 2020):405-413.

50

Saikiran Kannan, “Did nasal rinsing help ASEAN control pandemic or swift action?” India Today (Jul. 24, 2020).

51

Peter A. McCullough et al., “The Pathophysiologic Basic and Clinical Rationale for Early Ambulatory Treatment of COVID-19,” The American Journal of Medicine V:134 I:1 (Jan. 1, 2021):16-22. doi.org/10.1016/j.amjmed.2020.07.003

52

Jianjun Gao et al, “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies,” BioScience Trends 14(1) (Mar. 26, 2020):72-73, Epub Feb.19, 2020, doi: 10.5582/bst.2020.01047.

53

National Health Commission & State Administration of Traditional Chinese Medicine, “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia,” (Mar. 3, 2020).

54

Aimee Quin, Interview with Robert F. Kennedy Jr., (Oct. 1, 2021).

55

AAPS, “Physician List & Guide to Home-Based COVID Treatment,” AAPS (Aug. 28, 2021).

56

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, “Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis,” JAMA Network 324(13) (Sept. 22, 2020):1330-1341.

57

University of Oxford, “Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests,” University of Oxford (Feb. 9, 2021).

58

Ly-Mee Yu, DPhil et al, “Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial,” The Lancet Vol. 398 Iss. 10303 (Aug. 10, 2021):843-855.

59

Aaron Z. Reyes et al, “Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Annals of the Rheumatic Diseases,” Ann Rheum Dis. 80(5) (May 2021):550-557.

60

Peter A. McCullough et al., “Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).” Reviews in Cardiovascular Medicine 21 no. 4 (Dec. 2020): 517-530.